Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Charge radius isotope shift across the N=126 shell gap.

Goddard PM, Stevenson PD, Rios A.

Phys Rev Lett. 2013 Jan 18;110(3):032503. Epub 2013 Jan 15.

PMID:
23373916
2.

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.

Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, Workman P.

Mol Cancer Ther. 2005 Jan;4(1):125-39.

3.

Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.

Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P.

Mol Cancer Ther. 2004 Mar;3(3):353-62.

4.

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.

Clin Cancer Res. 1997 Nov;3(11):2063-74.

5.

Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.

Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE.

J Pharmacol Exp Ther. 1997 Apr;281(1):420-7.

PMID:
9103525
6.

Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors.

Barrie SE, Haynes BP, Potter GA, Chan FC, Goddard PM, Dowsett M, Jarman M.

J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):347-51.

PMID:
9219927
7.

Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.

Coley HM, Jarman M, Brooks N, Kubota T, Goddard PM, Jones M, Lee N, Owens MD, Halbert GW, Judson IR.

Int J Cancer. 1996 Nov 4;68(3):356-63.

8.

The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.

Coley HM, Jarman M, Jones M, Sargent JM, Kubota T, Lee NC, Goddard PM, Elgie AW, Williamson C, Taylor CG, Judson IR.

Anticancer Res. 1996 Jul-Aug;16(4A):1851-5.

PMID:
8712712
9.

Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.

Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.

Anticancer Res. 1996 Jan-Feb;16(1):33-8.

PMID:
8615631
10.

Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.

Kelland LR, Barnard CF, Evans IG, Murrer BA, Theobald BR, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, et al.

J Med Chem. 1995 Aug 4;38(16):3016-24.

PMID:
7636864
11.

A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.

Kelland LR, Barnard CF, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR.

Cancer Res. 1994 Nov 1;54(21):5618-22.

12.

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M.

J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73.

PMID:
7918112
13.

Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.

McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR.

Cancer Res. 1994 Aug 1;54(15):4118-22.

14.

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.

Cancer Res. 1993 Jun 1;53(11):2581-6.

16.

Platinum coordination complexes which circumvent cisplatin resistance.

Harrap KR, Kelland LR, Jones M, Goddard PM, Orr RM, Morgan SE, Murrer BA, Abrams MJ, Giandomenico CM, Cobbleigh T.

Adv Enzyme Regul. 1991;31:31-43.

PMID:
1877393
17.

Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity.

Rowlands MG, Parr IB, McCague R, Jarman M, Goddard PM.

Biochem Pharmacol. 1990 Jul 15;40(2):283-9.

PMID:
2165403
18.

The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.

Goddard PM, Jones M, Pollard LA, Valenti MR, Harrap KR.

Cancer Chemother Pharmacol. 1990;25(5):377-9.

PMID:
2155065
20.

Triazene metabolism. IV. Derivatives of hydroxymethyltriazenes: potential prodrugs for the active metabolites of the anti-tumour triazene, DTIC.

Cameron LM, LaFrance RJ, Hemens CM, Vaughan K, Rajaraman R, Chubb DC, Goddard PM.

Anticancer Drug Des. 1985 Oct;1(1):27-36.

PMID:
3870878
21.

Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.

Wilman DE, Cox PJ, Goddard PM, Hart LI, Merai K, Newell DR.

J Med Chem. 1984 Jul;27(7):870-4.

PMID:
6737430
22.
23.
24.

Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.

Giraldi T, Nisi C, Connors TA, Goddard PM.

J Med Chem. 1977 Jun;20(6):850-3.

PMID:
874961
25.

Tumour inhibitory triazenes: structural requirements for an active metabolite.

Connors TA, Goddard PM, Merai K, Ross WC, Wilman DE.

Biochem Pharmacol. 1976 Feb 1;25(3):241-6. No abstract available.

PMID:
1267820

Supplemental Content

Loading ...
Support Center